Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Healthcare Company (ACHC) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Acadia Healthcare Company (ACHC) over the last 14 years, with Q3 2025 value amounting to $427070.0.

  • Acadia Healthcare Company's Gains from Sales and Divestitures rose 2477.98% to $427070.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $427070.0, marking a year-over-year increase of 2477.98%. This contributed to the annual value of $365871.0 for FY2024, which is 7401.84% down from last year.
  • As of Q3 2025, Acadia Healthcare Company's Gains from Sales and Divestitures stood at $427070.0, which was up 2477.98% from $374741.0 recorded in Q2 2025.
  • Acadia Healthcare Company's 5-year Gains from Sales and Divestitures high stood at $1.4 million for Q1 2023, and its period low was $192282.0 during Q1 2024.
  • Over the past 5 years, Acadia Healthcare Company's median Gains from Sales and Divestitures value was $374741.0 (recorded in 2025), while the average stood at $591945.5.
  • As far as peak fluctuations go, Acadia Healthcare Company's Gains from Sales and Divestitures surged by 17160.38% in 2023, and later tumbled by 8634.55% in 2024.
  • Quarter analysis of 5 years shows Acadia Healthcare Company's Gains from Sales and Divestitures stood at $366048.0 in 2021, then surged by 41.64% to $518474.0 in 2022, then skyrocketed by 171.6% to $1.4 million in 2023, then plummeted by 74.02% to $365871.0 in 2024, then increased by 16.73% to $427070.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $427070.0 for Q3 2025, versus $374741.0 for Q2 2025 and $237478.0 for Q1 2025.